Turn down the football game and bring out the pies, it’s that time again! Stock Gumshoe is mostly closed down for the holiday week, but we do have to continue our annual tradition of calling out our “Turkey of the Year” … so take a pause from arguing with your family and join us, won’t […]
Articles
- Most Relevant
- Most Recent
For those who are curious about what I’m doing with my personal portfolio, I should note that I’ve let the cash balance build up a little bit (mostly through savings, not sales), and that I’ve had a couple transactions this week — I sold Teva (TEVA) as their strategy has morphed away from what I […]
A big part of the advertising that comes out for Carla Pasternak’s High Income Investing is by way of their writeups on the “income security of the month” — and, as she has done this month, she often recycles these ideas … it looks like today’s “Income Security of the Month” was also the income security of the Month for October.
Times are tough, everyone’s cutting back — so no need to hire another copywriter if you’ve got a perfectly good sales letter sitting around!
Some of the comments below first appeared in this space back then, which now seems a lifetime ago, but I’ve added some more info and done some updating.
“These special hybrid securities not only provide strong returns during market turmoil thanks to the ‘AAA’-rated portfolio of their parent company — they also provide unlimited upside potential since the shares are convertible at any time into stock of the underlying company.”
I feel like I’m waggling back and forth on a strange tightrope, as I’ve been doing for about a year and a half now, and I sum it up kinda like this: I’m quite nervous about the valuations of the overall market and about the massive debt load for both governments and individuals in the […]
Today I’m looking for the first time at a teaser ad from Bill Shaw, who is the Senior Analyst for Stansberry’s precious metals service — that service is now called Stansberry Gold & Silver Investor, and it’s one of the “no refunds, get a portfolio all at once” services that Stansberry has been pushing lately. […]
Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
[ed. note: Gumshoe readers have been delighted with the biotech stock discussion led by one of our readers, who has gone by the name karmaswimswami as he has shared hundreds of useful comments — so we’ve asked him to come on as a formal contributor, he’ll be sharing a column with the Irregulars and talking […]
We turn once again, dear friends, to my favorite kind of newsletter teaser ad: the promotion of “one little company” as the linchpin investment for exposure to a huge global trend. This time, it’s Alex Koyfman promoting his Penny Stock Millionaire newsletter ($999/year) by promising to reveal the name of a little “Super Battery” company […]
I’ve gotten quite a few questions about the latest pitch from Ian Wyatt for his $100K Portfolio newsletter — this is his letter that tracks the trades of a $100,000 real money portfolio of his own money, started up a couple years ago when every newsletter publisher was trying out a “real money” letter. I […]
[ed note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who shares his non-investment thoughts with us a couple times a month. I suppose it’s a coincidence that he’s looking at depression at a time when we’re all a bit depressed about the market, but maybe […]
Markel released their earnings last night, and they were, well, typical very good Markel earnings — they actually had an above average year in some ways, with good underwriting and not much catastrophe loss and good increases in sales (written premiums). And now, after crashing to about 1.05X book value after announcing the Alterra acquisition, […]
Exponential Tech Investor is a relatively new newsletter service from the Bonner & Partners stable, but that Bonner/Agora connection means it’s getting a lot of play — and we’ve seen a lot of questions about this latest pitch for the service that hints at a “Tiny Device” that editor Jeff Brown says is “Changing the […]
This is now the second time we’ve seen a “nighttime solar energy” pick from the folks at Angel Publishing — last time it was for a solar spray-on film innovation, in a pitch for Green Chip Stocks Premium where they claimed that a company had “perfected sunless solar,” and this time it’s a pitch from […]
Well, we’ve already covered one non-stock idea this week (that was the “Phi Account” pitch about philatelic investments) … so we might as well jump right in and look at another. This time, it’s a lot easier and is based on pocket change. And no, it’s not the same pitch for pre-1965 coins that have […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his non-investing thoughts with us once or twice a month. His words and thoughts are his own. My eyes are red this time of year, so I read this one with interest.] Just about […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
Does the Supreme Court decision announced June 17th, giving the FDA the right to sue pharmaceutical companies that enter into “pay to delay” agreements with generic drug makers represent a blow to big pharma, a gift to the generic sector, and a boon to consumers? I don’t think so, and here’s why: The situations where […]
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
ACT NATURALLY – Beatles/Buck Owens Cover – Barry Gonen https://youtu.be/xj3EVCKzyck Only the best tunes and investments musings in the music musings industry allowed. Rock on! – >>>—Jammin’——>
[Ed. Note: Myron Martin is a longtime reader who writes for the Irregulars a couple times a month about junior miners and other stocks that strike his fancy. Below is his latest contribution. As always, he’s agreed to our trading restrictions and his words and opinions are his own.] Happy Anniversary Gumshoers! Hard to believe, […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He choses his own topics, and his words and opinions are his own. Part one of this series is here if you missed it. Enjoy!] “The heat was hot and the ground was dry but the air was full of sound. I’ve […]
Nick Hodge has been focusing a lot on biotech-ish companies for his Early Advantage newsletter lately, and they usually end up being pretty early-stage stocks with good stories about some kind of breakthrough or unique compound or device and no real financials yet (meaning, little to no revenue or earnings) — just the kind of […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his non-investing thoughts with us once or twice a month. His words and thoughts are his own. My eyes are red this time of year, so I read this one with interest.] Just about […]
I think I saw this ad a few months ago and didn’t write about it for one reason or another, but it just started a heavy rotation again — so let’s have a gander. David Gardner is a growth stock dynamo — he and his brother Tom founded the Motley Fool as an AOL chat […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] Let me begin with a disclaimer: I am not skinny, but neither am I fat. This chapter […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!] In June 1962, women working in the dressmaking arm of a certain American textile factory were overcome with fear. Rumors began […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] The word “placebo” is the first person singular, future tense, of the Latin verb “placere,” to please […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!] Lying in bed beneath an exam lamp, my 16-year-old patient’s facial serenity belied how fervently he was kneading misbaha beads with […]
[ed note: We got a lot of questions about this pitch after we solved a different DeHaemer teaser yesterday, so we’ve brought it up for all to see again. The stock spiked up in the Spring, a few months after this article first ran back in January, but has come back down to a bit […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own. Enjoy!] In the Saturday morning Looney Tunes many of us saw as children, one trope always stuck with me: that of the grand piano falling from way up high and crashing, splintering itself. There’s a […]
This month I want to take a look at a stock I’ve mentioned in the past, but have not yet personally bought. But first, I thought I’d call your attention to another wave of negativity that could be hitting Seadrill (SDRL) shares — Elliot Gue, who was one of the first newsletter folks to call […]
[what follows was originally published in 2012 and 2013, it has not been updated (the pitch for the service remains similar, presumably the strategy does as well) but is being brought up to the top of the page because so many readers are asking about it this week.] It appears that Porter Stansberry is pushing […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
Paul Goodwin edits the Cabot China and Emerging Markets report, which is really the only surviving China-focused newsletter I can think of from a big publisher (most publishers had such a letter during the China bull run in the mid-late 2000s, but many of them disappeared in recent years as China got to be as […]
These kinds of secret income pitches get sent around all the time, and that’s been true ever since Stock Gumshoe started publishing in 2007 — some of our very first articles were about deciphering the “secrets” behind schemes described as “801k Plans” (because they’re “twice as good as 401k plans“) and other terms that are […]
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
Those who are Irregulars know that I own shares of Ligand (LGND) and suggested it last summer in the mid-$30s, and have nibbled personally on the way up. My reasons for liking Ligand are basically two: They have a royalty-driven business model that provides potential upside with low capital needs; and they have a focus […]
[Ed. Note: Myron Martin is a longtime reader who writes for the Irregulars a couple times a month about junior miners and other stocks that strike his fancy. Below is his latest contribution. As always, he’s agreed to our trading restrictions and his words and opinions are his own.] Happy Anniversary Gumshoers! Hard to believe, […]